Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;87(5):587-598.
doi: 10.1007/s00280-021-04256-8. Epub 2021 Mar 20.

Anticancer potential of metformin: focusing on gastrointestinal cancers

Mohammad Rafi Khezri  1 , Hassan Malekinejad  2   3 , Naime Majidi-Zolbanin  1   4 , Morteza Ghasemnejad-Berenji  5   6
Affiliations
Review

Anticancer potential of metformin: focusing on gastrointestinal cancers

Mohammad Rafi Khezri et al. Cancer Chemother Pharmacol. 2021 May.

Erratum in

Abstract

Gastrointestinal cancers are one of the most common types of cancer that have high annual mortality; therefore, identification and introduction of safe drugs in the control and prevention of these cancers are of particular importance. Metformin, a lipophilic biguanide, is the most commonly prescribed agent for type 2 diabetes management. In addition to its great effects on lowering the blood glucose concentrations, the anti-cancer properties of this drug have been reported in many types of cancers such as gastrointestinal cancers. Hence the effects of this agent as a safe drug on the reduction of gastrointestinal cancer risk and suppression of these types of cancers have been studied in different clinical trials. Furthermore, the proposed mechanisms of metformin in preventing the growth of these cancers have been investigated in several studies. In this review, we discuss recent advances in elucidating the molecular mechanisms that are relevant for metformin use in gastrointestinal cancer treatment.

Keywords: Cancer; Gastrointestinal; Metformin.

PubMed Disclaimer

References

    1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S (2012) Cancer treatment and survivorship statistics 2012. CA Cancer J Clin 62(4):220–241 - PubMed
    1. Society AC (2014) Cancer facts and figures 204. Am Cancer Soc 4:10–40
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018) Global cancer observatory: cancer today. Lyon France Internat Agency Res Cancer 33:190–230
    1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305 - PubMed - PMC
    1. Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754):1642–1646 - PubMed - PMC

MeSH terms

LinkOut - more resources